Issues related to antimicrobial resistance. H.R. 2940/S.1355 - The PASTEUR Act.
Issues related to the importation of non-human primates.
Duration: January 1, 2009
to
February 28, 2022
General Issues: Health Issues , Natural Resources , Medicare/Medicaid , Pharmacy , Taxation/Internal Revenue Code , Copyright/Patent/Trademark , Fuel/Gas/Oil , Budget/Appropriations , Foreign Relations , Financial Institutions/Investments/Securities , Medical/Disease Research/Clinical Labs , Small Business , Labor Issues/Antitrust/Workplace
Spending: about $2,880,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2009: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), White House Office, Executive Office of the President (EOP)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Jonathon Jones
Chief of Staff, Senator Carper
Legislative Director, Senator Carper
Sheila Murphy
Legislative Director, Senator Klobuchar
Legislative Director, Rep. Richard Durbin
Legislative Director, Senator Bob Kerrey
Legislative Director, Senator Ben Nelson
Legislative Director, Senator Tom Carper
LD and Interim COS, Senator Amy Klobuchar
Subcomm. on Fed. Financial Mgmnt
Senior Foreign Policy Advisor, Senator Daschle
LD, Senator Klobuchar
Jeff Peck
Staff Director, Senate Judiciary Committee
John Michael Gonzalez
Chief of Staff, Rep. Chris Bell
Chief of Staff, Rep. Melissa Bean
CoS, Representative Bean
Jeff Shapiro
Senior Legislative Assistant, Rep. Lee Terry
Chief of Staff, Rep. Adrian Smith
Justin McCarthy
Legislative Correspondent, Rep. Thomas Ewing
Legislative Assistant, Rep. Thomas Ewing
Assist. USTR, Intergvmental and Pub. Affairs
Assistant USTR, Congressional Affairs
Special Assistant to the President, Leg. Affairs
Sean Richardson
Chief of Staff, Senator Amy Klobuchar
Chief of Staff, Rep. Patrick Kennedy
Dpty Staff Dir, Dem Tech and Com. Committee
Policy Advisor, Rep. Dick Gephardt
Staff Assistant, Rep. Dick Gephardt
Chief of Staff, Senator Klobuchar
Chief of Staff, Sen. Amy Klobuchar (2006-2007); Chief of Staff, Rep. Patrick Kennedy (2002-2007); Deputy Staff Dir., Senate Democratic Conference Committee (1999-2002)
Janet Mullins Grissom
Assist. Sec., Leg. Affairs, State Department
Chief of Staff, Senator Mitch McConnell
Chief of Staff, Senator Bob Packwood
Assist. to the President, Political Affairs
John Twomey
Chief of Staff, HHS Office of the Asst. Sec. for Legislation (2019-2021); Policy Adviser, HHS (2017-2019); Special Asst., Office of the Secretary, HHS (2017); Staff Assistant, Rep. Tom Price (2015-2017); Intern, Rep. Doug Collins (2015)
Andrew McKechnie
Health Policy Adviser, Sen. Finance Cmte. (2009-2010); Legislative
Assistant, Sen. Norm Coleman (2007-2008); Legislative Assistant, Rep.
Jim Ramstad (2005-2007); Staff Assistant, Rep. Jim Ramstad (2005)
Bryant Hall
Staff Director, Sen. Veterans Affairs Committee (2003-2004); Legislative Director, Sen. Bob Graham (1999-2003)
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Tiber Creek Group lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on April 15.
Original Filing: 301549496.xml
Lobbying Issues
Issues related to antimicrobial resistance. H.R. 2940/S.1355 - The PASTEUR Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
Lobbying Issues
Issues related to the importation of non-human primates.
4th Quarter, 2023
In Q4, Tiber Creek Group lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on Jan. 14.
Original Filing: 301524283.xml
Lobbying Issues
Issues related to antimicrobial resistance. H.R. 2940/S. 1355 - The PASTEUR Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
Lobbying Issues
Issues related to the importation of non-human primates.
3rd Quarter, 2023
In Q3, Tiber Creek Group lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on Oct. 13, 2023.
Original Filing: 301500425.xml
Lobbying Issues
Issues related to antimicrobial resistance. H.R. 2940/S. 1355 - The PASTEUR Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
Lobbying Issues
Issues related to the importation of non-human primates.
2nd Quarter, 2023
In Q2, Tiber Creek Group lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on July 14, 2023.
Original Filing: 301476169.xml
Lobbying Issues
Issues related to antimicrobial resistance. H.R. 3932/S. 2076 - The PASTEUR Act. Consolidated Appropriations Act, 2023 (PL 117-328).
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
Lobbying Issues
Issues related to the importation of non-human primates.
1st Quarter, 2023
In Q1, Tiber Creek Group lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on April 16, 2023.
Original Filing: 301452372.xml
Lobbying Issues
Issues related to antimicrobial resistance. H.R. 3932/S. 2076 - The PASTEUR Act. Consolidated Appropriations Act, 2023 (PL 117-328).
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
Lobbying Issues
Issues related to the importation of non-human primates.
4th Quarter, 2022
In Q4, Tiber Creek Group lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on Jan. 16, 2023.
Original Filing: 301428641.xml
Lobbying Issues
Issues related to antimicrobial resistance.; H.R. 3932/S. 2076 - The PASTEUR Act. Consolidated Appropriations Act, 2023 (PL 117-328).
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
3rd Quarter, 2022
In Q3, Tiber Creek Group lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on Oct. 16, 2022.
Original Filing: 301405032.xml
Lobbying Issues
Issues related to antimicrobial resistance.; H.R. 3932/S. 2076 - The PASTEUR Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
2nd Quarter, 2022
In Q2, Tiber Creek Group lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on July 18, 2022.
Original Filing: 301382495.xml
Lobbying Issues
Issues related to antimicrobial resistance.; H.R. 3932/S. 2076 - The PASTEUR Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
1st Quarter, 2022
In Q1, Tiber Creek Group lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on April 19, 2022.
Original Filing: 301360282.xml
Lobbying Issues
Issues related to antimicrobial resistance issues and reimbursement; H.R. 3932/S. 2076 - The PASTEUR Act; Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Executive Office of the President (EOP)
1st Quarter, 2022
Tiber Creek Group terminated an engagement in which they represented Biotechnology Innovation Organization (BIO) on April 16, 2022.
Original Filing: 301357390.xml
Lobbying Issues
Issues related to antimicrobial resistance issues and reimbursement; H.R. 3932/S. 2076 - The PASTEUR Act; Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Executive Office of the President (EOP)
4th Quarter, 2021
In Q4, Tiber Creek Group lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on Jan. 18, 2022.
Original Filing: 301325109.xml
Lobbying Issues
Issues related to antimicrobial resistance issues and reimbursement; H.R. 3932/S. 2076 - The PASTEUR Act; Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Executive Office of the President (EOP)
3rd Quarter, 2021
In Q3, Tiber Creek Group lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on Oct. 18, 2021.
Original Filing: 301301381.xml
Lobbying Issues
Issues related to antimicrobial resistance issues and reimbursement; H.R. 3932/S. 2076 - The PASTEUR Act; Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office
2nd Quarter, 2021
In Q2, Tiber Creek Group lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on July 19, 2021.
Original Filing: 301280268.xml
Lobbying Issues
Issues related to antimicrobial resistance issues and reimbursement. H.R.3932/S.2076 - The Pioneering Antimicrobial Subscriptions To End Up surging Resistance Act of 2020 or The PASTEUR Act. Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office
1st Quarter, 2021
In Q1, Peck Madigan Jones did no lobbying for Biotechnology Innovation Organization (BIO) . The report was filed on April 19, 2021.
Original Filing: 301258738.xml
4th Quarter, 2015
Peck Madigan Jones terminated an engagement in which they represented BIO on Jan. 20, 2016.
Original Filing: 300779052.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Issues relating to the impact of the biotech industry. Issues related to biosimilars. H.R. 6, 21st Century Cures Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposed Medicare and Medicaid cuts, including changes to Part D and Part B.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
R&D tax credit. EXPIRE Act of 2014.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 9, Innovation Act. S. 1137, the PATENT Act. Issues regarding patent reform.
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2015
In Q3, Peck Madigan Jones lobbied for BIO , earning $80,000. The report was filed on Oct. 20, 2015.
Original Filing: 300762614.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Issues relating to the impact of the biotech industry. Issues related to biosimilars. H.R. 6, 21st Century Cures Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposed Medicare and Medicaid cuts, including changes to Part D and Part B.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
R&D tax credit. EXPIRE Act of 2014.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 9, Innovation Act. S. 1137, the PATENT Act. Issues regarding patent reform.
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2015
In Q2, Peck Madigan Jones lobbied for BIO , earning $80,000. The report was filed on July 20, 2015.
Original Filing: 300745216.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Issues relating to the impact of the biotech industry. Issues related to biosimilars. H.R. 6, 21st Century Cures Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposed Medicare and Medicaid cuts, including changes to Part D and Part B.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
R&D tax credit. EXPIRE Act of 2014.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 9, Innovation Act. S. 1137, the PATENT Act. Issues regarding patent reform.
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2015
In Q1, Peck Madigan Jones lobbied for BIO , earning $80,000. The report was filed on April 20, 2015.
Original Filing: 300727427.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Legislation impacting patent settlements. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Issues relating to the impact of the biotech industry. Issues related to biosimilars.
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposed Medicare and Medicaid cuts, including changes to Part D and Part B.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
R&D tax credit. EXPIRE Act of 2014.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitoring of renewable fuel standard, including EPA's proposed ethanol rules.
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office
Lobbying Issues
S. Con. Res 11, Senate budget resolution.
Lobbying Issues
H.R. 9, Innovation Act, and Senate discussions regarding patent reform.
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2014
In Q4, Peck Madigan Jones lobbied for BIO , earning $80,000. The report was filed on Jan. 20, 2015.
Original Filing: 300705639.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Legislation impacting patent settlements. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Issues relating to the impact of the biotech industry. Issues related to biosimilars.
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Proposed Medicare and Medicaid cuts, including changes to Part D and Part B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
R&D Tax Credit. S.2260, EXPIRE Act of 2014.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitoring of renewable fuel standard, including EPA's proposed ethanol rules.
Agencies Lobbied
White House Office U.S. House of Representatives U.S. Senate
Lobbying Issues
International treaty on plant genetic resources for food and agriculture.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2014
In Q3, Peck Madigan Jones lobbied for BIO , earning $80,000. The report was filed on Oct. 20, 2014.
Original Filing: 300686107.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Legislation impacting patent settlements. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Issues relating to the impact of the biotech industry. Issues related to biosimilars.
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Proposed Medicare and Medicaid cuts, including changes to Part D and Part B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
R&D Tax Credit. S.2260, EXPIRE Act of 2014.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitoring of renewable fuel standard, including EPA's proposed ethanol rules.
Agencies Lobbied
White House Office U.S. House of Representatives U.S. Senate
Lobbying Issues
International treaty on plant genetic resources for food and agriculture.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2014
In Q2, Peck Madigan Jones lobbied for BIO , earning $80,000. The report was filed on July 21, 2014.
Original Filing: 300667436.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Legislation impacting patent settlements. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Issues relating to the impact of the biotech industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Legislation impacting patent settlements. Proposed Medicare and Medicaid cuts, including changes to Part D and Part B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
R&D Tax Credit. S.2260, EXPIRE Act of 2014.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitoring of renewable fuel standard, including EPA's proposed ethanol rules.
Agencies Lobbied
White House Office U.S. House of Representatives U.S. Senate
Lobbying Issues
International treaty on plant genetic resources for food and agriculture.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2014
In Q1, Peck Madigan Jones lobbied for BIO , earning $80,000. The report was filed on April 21, 2014.
Original Filing: 300646470.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Legislation impacting patent settlements. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Issues relating to the impact of the biotech industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Legislation impacting patent settlements. Proposed Medicare and Medicaid cuts, including changes to Part D and Part B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.J. Res. 59, Continuing Appropriations Resolution, 2014 and budget deal. The sequester as it relates to FDA user fees.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitoring of renewable fuel standard, including EPA's proposed ethanol rules.
Agencies Lobbied
White House Office U.S. House of Representatives U.S. Senate
4th Quarter, 2013
In Q4, Peck Madigan Jones lobbied for BIO , earning $80,000. The report was filed on Jan. 21, 2014.
Original Filing: 300623005.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Legislation impacting patent settlements. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Issues relating to the impact of the biotech industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Legislation impacting patent settlements. Proposed Medicare and Medicaid cuts, including changes to Part D and Part B. "Track and Trace" legislation. Drug imporation. H.R. 3204, Drug Quality and Security Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.J. Res. 59, Continuing Appropriations Resolution, 2014 and budget deal. The sequester as it relates to FDA user fees.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Orphan Drug Tax Credit. R&D Tax Credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitoring of renewable fuel standard, including EPA's proposed ethanol rules.
Agencies Lobbied
White House Office U.S. House of Representatives U.S. Senate
3rd Quarter, 2013
In Q3, Peck Madigan Jones lobbied for BIO , earning $80,000. The report was filed on Oct. 21, 2013.
Original Filing: 300604158.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Legislation impacting patent settlements. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Issues relating to the impact of the biotech industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Drug importation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Legislation impacting patent settlements. Proposed Medicare and Medicaid cuts, including changes to Part D and Part B. "Track and Trace" legislation. Drug imporation. H.R. 3204, Drug Quality and Security Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
The sequester as it relates to FDA user fees and drug imporation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Orphan Drug Tax Credit. R&D Tax Credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2013
In Q2, Peck Madigan Jones lobbied for BIO , earning $80,000. The report was filed on July 22, 2013.
Original Filing: 300582859.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Legislation impacting patent settlements. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Issues relating to the impact of the biotech industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Drug importation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Legislation impacting patent settlements. Proposed Medicare and Medicaid cuts, including changes to Part D and Part B. "Track and Trace" legislation. Drug imporation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
The sequester as it relates to FDA user fees and drug imporation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Orphan Drug Tax Credit. R&D Tax Credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2013
In Q1, Peck Madigan Jones lobbied for BIO , earning $80,000. The report was filed on April 22, 2013.
Original Filing: 300562078.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Legislation impacting patent settlements. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Issues relating to the impact of the biotech industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Drug importation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Legislation impacting patent settlements. Proposed Medicare and Medicaid cuts, including changes to Part D and Part B. "Track and Trace" legislation. Drug imporation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
The sequester as it relates to FDA user fees and drug imporation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2012
In Q4, Peck Madigan Jones lobbied for BIO , earning $80,000. The report was filed on Jan. 22, 2013.
Original Filing: 300539047.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. S.27, Preserve Access to Affordable Generics Act. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.27, Preserve Access to Affordable Generics Act. Proposed Medicare and Medicaid cuts, including changes to Part D and Part B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2012
In Q3, Peck Madigan Jones (formerly Peck, Madigan, Jones & Stewart, Inc.) lobbied for BIO , earning $80,000. The report was filed on Oct. 22, 2012.
Original Filing: 300520420.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. S.27, Preserve Access to Affordable Generics Act. S. 3187, the Food and Drug Administration Safety and Innovation Act. Proposed Medicare and Medicaid cuts. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.27, Preserve Access to Affordable Generics Act. S. 3187, the Food and Drug Administration Safety and Innovation Act.
Proposed Medicare and Medicaid cuts. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2012
In Q2, Peck, Madigan, Jones & Stewart, Inc. lobbied for BIO , earning $80,000. The report was filed on July 20, 2012.
Original Filing: 300495396.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. S.27, Preserve Access to Affordable Generics Act. S. 3187, the Food and Drug Administration Safety and Innovation Act. Proposed Medicare and Medicaid cuts. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.27, Preserve Access to Affordable Generics Act. S. 3187, the Food and Drug Administration Safety and Innovation Act.
Proposed Medicare and Medicaid cuts. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.1933, Reopening American Capital Markets to Emerging Growth Companies Act of 2011. H.R. 3606, Jumpstart Our Business Startups Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Financial Institutions/Investments/Securities
1st Quarter, 2012
In Q1, Peck, Madigan, Jones & Stewart, Inc. lobbied for BIO , earning $80,000. The report was filed on April 20, 2012.
Original Filing: 300474891.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. S.27, Preserve Access to Affordable Generics Act. Reauthorization of the Prescription Drug User Fee Act. Proposed Medicare and Medicaid cuts, including changes to ASP formula in Medicare Part B.
S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts, including changes to ASP formula in Medicare Part B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.27, Preserve Access to Affordable Generics Act. Reauthorization of the Prescription Drug User Fee Act.
Proposed Medicare and Medicaid cuts, including changes to ASP formula in Medicare Part B. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.1933, Reopening American Capital Markets to Emerging Growth Companies Act of 2011. H.R. 3606, Jumpstart Our Business Startups Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Financial Institutions/Investments/Securities
4th Quarter, 2011
In Q4, Peck, Madigan, Jones & Stewart, Inc. lobbied for BIO , earning $80,000. The report was filed on Jan. 20, 2012.
Original Filing: 300449813.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. S.27, Preserve Access to Affordable Generics Act. Reauthorization of the Prescription Drug User Fee Act. Proposed Medicare and Medicaid cuts, including changes to ASP formula in Medicare Part B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts, including changes to ASP formula in Medicare Part B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.27, Preserve Access to Affordable Generics Act. Reauthorization of the Prescription Drug User Fee Act.
Proposed Medicare and Medicaid cuts, including changes to ASP formula in Medicare Part B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2011
In Q3, Peck, Madigan, Jones & Stewart, Inc. lobbied for BIO , earning $80,000. The report was filed on Oct. 20, 2011.
Original Filing: 300424846.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. S.319, Pharmaceutical Market Access and Drug Safety Act of 2011. Changes to the 340b program. S.27, Preserve Access to Affordable Generics Act. Reauthorization of the Prescription Drug User Fee Act. Proposed Medicare and Medicaid cuts in debt limit negotiations, including proposed cuts to Part B reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts in debt limit negotiations, including proposed cuts to Part B reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.319, Pharmaceutical Market Access and Drug Safety Act of 2011. Changes to the 340b program. S.27, Preserve Access to Affordable Generics Act. Reauthorization of the Prescription Drug User Fee Act.
Proposed Medicare and Medicaid cuts in debt limit negotiations, including proposed cuts to Part B reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Changes to the 340b program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.23, America Invents Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2011
In Q2, Peck, Madigan, Jones & Stewart, Inc. lobbied for BIO , earning $80,000. The report was filed on July 20, 2011.
Original Filing: 300402049.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. S.319, Pharmaceutical Market Access and Drug Safety Act of 2011. Changes to the 340b program. S.27, Preserve Access to Affordable Generics Act. Qualifying Therapeutic Discovery Project tax credit. Reauthroization of the Prescription Drug User Fee Act. Proposed Medicare and Medicaid cuts in debt limit negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts in debt limit negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.319, Pharmaceutical Market Access and Drug Safety Act of 2011. Changes to the 340b program. S.27, Preserve Access to Affordable Generics Act. Reauthroization of the Prescription Drug User Fee Act.
Proposed Medicare and Medicaid cuts in debt limit negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Changes to the 340b program. Qualifying Therapeutic Discovery Project tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Qualifying Therapeutic Discovery Project tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.23, America Invents Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2011
In Q1, Peck, Madigan, Jones & Stewart, Inc. lobbied for BIO , earning $80,000. The report was filed on April 20, 2011.
Original Filing: 300376151.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. S.319, Pharmaceutical Market Access and Drug Safety Act of 2011. Changes to the 340b program. S.27, Preserve Access to Affordable Generics Act. Qualifying Therapeutic Discovery Project tax credit. Reauthroization of the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.319, Pharmaceutical Market Access and Drug Safety Act of 2011. Changes to the 340b program. S.27, Preserve Access to Affordable Generics Act. Reauthroization of the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Changes to the 340b program. Qualifying Therapeutic Discovery Project tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Qualifying Therapeutic Discovery Project tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.23, America Invents Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2010
In Q4, Peck, Madigan, Jones & Stewart, Inc. lobbied for BIO , earning $80,000. The report was filed on Jan. 20, 2011.
Original Filing: 300352645.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. Changes to the 340b program. S.369, Preserve Access to Affordable Generics Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. Changes to the 340b program. S.369, Preserve Access to Affordable Generics Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Changes to the 340b program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S. 1233, Small Business Innovation Research program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.4899, Supplemental Appropriations Act of 2010: Bioshield Special Reserve Fund; Patent Settlement provisions; 340b provisions.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.515, Patent Reform Act of 2009.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2010
In Q3, Peck, Madigan, Jones & Stewart, Inc. lobbied for BIO , earning $80,000. The report was filed on Oct. 20, 2010.
Original Filing: 300327147.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. Changes to the 340b program. S.369, Preserve Access to Affordable Generics Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. Changes to the 340b program. S.369, Preserve Access to Affordable Generics Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Changes to the 340b program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S. 1233, Small Business Innovation Research program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.4899, Supplemental Appropriations Act of 2010: Bioshield Special Reserve Fund; Patent Settlement provisions; 340b provisions.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.515, Patent Reform Act of 2009.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2010
In Q2, Peck, Madigan, Jones & Stewart, Inc. lobbied for BIO , earning $80,000. The report was filed on July 20, 2010.
Original Filing: 300297808.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. H.R. 1548, Pathway for Biologics Act. H.R. 2502, Comparative Effectiveness Research Act of 2009. Changes to the 340b program. H.R.4213, American Jobs and Closing Tax Loopholes Act of 2010: AMP provision; 340b provisions.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. Support for H.R. 1548, Pathway for Biologics Act. H.R. 2502, Comparative Effectiveness Research Act of 2009. Changes to the 340b program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Support for H.R. 1548, Pathway for Biologics Act. H.R. 2502, Comparative Effectiveness Research Act of 2009. Changes to the 340b program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S. 1233, Small Business Innovation Research program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.4899, Supplemental Appropriations Act of 2010: Bioshield Special Reserve Fund; Patent Settlement provisions; 340b provisions.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.515, Patent Reform Act of 2009.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2010
In Q1, Peck, Madigan, Jones & Stewart, Inc. lobbied for BIO , earning $80,000. The report was filed on April 20, 2010.
Original Filing: 300270866.xml
Lobbying Issues
H.R.3590, Patient Protection and Affordable Care Act. H.R.4872, Health Care and Education Reconciliation Act of 2010. H.R. 3962, Affordable Health Care for America Act. Medicaid Drug Rebates. Reforms to Medicare Part D. S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. H.R. 1548, Pathway for Biologics Act. H.R. 2502, Comparative Effectiveness Research Act of 2009. Changes to the 340b program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.3590, Patient Protection and Affordable Care Act. H.R.4872, Health Care and Education Reconciliation Act of 2010. H.R. 3962, Affordable Health Care for America Act. Medicaid Drug Rebates. Reforms to Medicare Part D.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. Support for H.R. 1548, Pathway for Biologics Act. H.R. 2502, Comparative Effectiveness Research Act of 2009. Changes to the 340b program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.3590, Patient Protection and Affordable Care Act. H.R.4872, Health Care and Education Reconciliation Act of 2010. H.R. 3962, Affordable Health Care for America Act. Support for H.R. 1548, Pathway for Biologics Act. H.R. 2502, Comparative Effectiveness Research Act of 2009. Changes to the 340b program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2009
In Q4, Peck, Madigan, Jones & Stewart, Inc. lobbied for BIO , earning $60,000. The report was filed on Jan. 20, 2010.
Original Filing: 300247996.xml
Lobbying Issues
H.R. 3200, America's Affordable Health Choices Act of 2009. S. 1796, Americas Healthy Future Act of 2009. S. 1679, Affordable Health Choices Act. Dorgan Amendment # 2793 to the Patient Protection and Affordable Care Act. Medicaid Drug Rebates. Reforms to Medicare Part D. S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. H.R. 1548, Pathway for Biologics Act. H.R. 2502, Comparative Effectiveness Research Act of 2009. Changes to the 340b program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3200, America's Affordable Health Choices Act of 2009. S. 1796, Americas Healthy Future Act of 2009. S. 1679, Affordable Health Choices Act. Medicaid Drug Rebates. Reforms to Medicare Part D.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. Dorgan Amendment # 2793 to the Patient Protection and Affordable Care Act. Support for H.R. 1548, Pathway for Biologics Act. H.R. 2502, Comparative Effectiveness Research Act of 2009. Changes to the 340b program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3200, America's Affordable Health Choices Act of 2009. S. 1796, Americas Healthy Future Act of 2009. S. 1679, Affordable Health Choices Act. Support for H.R. 1548, Pathway for Biologics Act. H.R. 2502, Comparative Effectiveness Research Act of 2009. Changes to the 340b program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2009
In Q3, Peck, Madigan, Jones & Stewart, Inc. lobbied for BIO , earning $60,000. The report was filed on Oct. 20, 2009.
Original Filing: 300219002.xml
Lobbying Issues
S. 515, The Patent Reform Act of 2009.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Development of health care reform legislation in Senate Finance Committee. Affordable Health Choices Act. Tri-Committee House bill. Medicaid Drug Rebates. Reforms to Medicare Part D. S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. McCain Amendment #4 to Affordable Health Choices Act. Support for H.R. 1548, Pathway for Biologics Act. S.CON.RES.13, The Senate Budget Resolution. H.CON.RES.85, The House Budget Resolution.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Development of health care reform legislation in Senate Finance Committee. Affordable Health Choices Act. Tri-Committee House bill. Medicaid Drug Rebates. Reforms to Medicare Part D.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. McCain Amendment #4 to Affordable Health Choices Act. S.CON.RES.13, The Senate Budget Resolution. H.CON.RES.85, The House Budget Resolution.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Development of health care reform legistlation in Senate Finance Committee. Affordable Health Choices Act. Tri-Committee House bill. Support for H.R. 1548, Pathway for Biologics Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2009
In Q2, Peck, Madigan, Jones & Stewart, Inc. lobbied for BIO , earning $60,000. The report was filed on July 20, 2009.
Original Filing: 300188257.xml
Lobbying Issues
S. 515, The Patent Reform Act of 2009.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Development of health care reform legislation in Senate Finance Committee. Affordable Health Choices Act. Tri-Committee House bill. Medicaid Drug Rebates. Reforms to Medicare Part D. S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. McCain Amendment #4 to Affordable Health Choices Act. Support for H.R. 1548, Pathway for Biologics Act. S.CON.RES.13, The Senate Budget Resolution. H.CON.RES.85, The House Budget Resolution.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Development of health care reform legislation in Senate Finance Committee. Affordable Health Choices Act. Tri-Committee House bill. Medicaid Drug Rebates. Reforms to Medicare Part D.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. McCain Amendment #4 to Affordable Health Choices Act. S.CON.RES.13, The Senate Budget Resolution. H.CON.RES.85, The House Budget Resolution.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Development of health care reform legistlation in Senate Finance Committee. Affordable Health Choices Act. Tri-Committee House bill. Support for H.R. 1548, Pathway for Biologics Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2009
In Q1, Peck, Madigan, Jones & Stewart, Inc. (formerly Johnson, Madigan, Peck, Boland & Stewart, Inc.) lobbied for BIO , earning $60,000. The report was filed on April 20, 2009.
Original Filing: 300163921.xml
Lobbying Issues
Health care reform; patent reform; follow-on biologics; and stem cell research.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Budget/Appropriations Health Issues Medicare/Medicaid Pharmacy
1st Quarter, 2009
JOHNSON, MADIGAN, PECK, BOLAND & STEWART, INC. filed a lobbying registration on Feb. 22, 2009 to represent BIO, effective Jan. 1, 2009.
Original Filing: 300138847.xml
Issue(s) they said they’d lobby about: Health care reform; patent reform; follow-on biologics; and stem cell research .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate